Scott Stringer, MD
Emergency Medicine · Sacramento, CANPI 1720196611
Payments from drug & device makers
Across 226 payments — averaging $49.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$1K
- Amgen$1K
- AbbVie$928
- Boehringer Ingelheim$886
- Lilly USA, LLC$636
- plus $5K from 30 others
What the payments were for
- Travel & lodging$30%
- Food & beverage$11,16899%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 40 | $1,566 |
| AstraZeneca(2 entities) | 19 | $1,358 |
| Amgen | 25 | $1,268 |
| AbbVie(2 entities) | 34 | $928 |
| Boehringer Ingelheim | 12 | $886 |
| Lilly USA, LLC | 13 | $636 |
| GSK | 9 | $481 |
| Novartis | 12 | $459 |
| Neurocrine Biosciences, Inc. | 5 | $382 |
| Novo Nordisk | 8 | $347 |
| Bayer | 3 | $327 |
| E.r. Squibb & Sons, L.L.C. | 3 | $319 |
| Corcept Therapeutics | 3 | $258 |
| Janssen Scientific Affairs, LLC | 4 | $234 |
| Sanofi-aventis U.S. LLC | 3 | $228 |
| Radius Health, Inc. | 4 | $173 |
| Pfizer | 4 | $143 |
| Bristol Myers Squibb | 1 | $137 |
| UCB, Inc. | 1 | $128 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $124 |
| Alcresta Therapeutics, Inc. | 1 | $122 |
| Verona Pharma, Inc. | 1 | $122 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Kowa Pharmaceuticals America, Inc. | 1 | $109 |
| Dexcom, Inc. | 1 | $73 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 5 | $37 |
| Sanofi | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Hu-friedy Mfg. Co., LLC | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,286 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 335 | $151,390 |
| FarxigaDapagliflozin Propanediol | 95 | $107,934 |
| XareltoRivaroxaban | 185 | $97,899 |
| JardianceEmpagliflozin | 126 | $94,442 |
| OzempicSemaglutide | 60 | $67,879 |
| MounjaroTirzepatide | 55 | $62,385 |
| JanuviaSitagliptin Phosphate | 29 | $29,405 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $28,651 |
| MyrbetriqMirabegron | 32 | $25,231 |
| NuedextaDextromethorphan Hbr/Quinidine | 35 | $23,776 |
| RybelsusSemaglutide | 15 | $18,823 |
| TrulicityDulaglutide | 15 | $17,417 |
| NamzaricMemantine Hcl/Donepezil Hcl | 45 | $17,178 |
| GemtesaVibegron | 17 | $16,732 |
| EntrestoSacubitril/Valsartan | 18 | $13,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $143 | $157,711367 claims |
| AstraZenecaFarxiga | $1,358 | $107,93495 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $886 | $107,475152 claims |
| Johnson & JohnsonXarelto | $1,566 | $97,899185 claims |
| Novo NordiskOzempic, Rybelsus | $347 | $86,70275 claims |
| Lilly USA, LLCMounjaro, Trulicity | $636 | $79,80270 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $481 | $32,83255 claims |
| MerckJanuvia | $17 | $29,40529 claims |
| AbbVieNamzaric | $928 | $17,17845 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $37 | $16,73217 claims |
| NovartisEntresto | $459 | $13,65618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,006 emergency medicine providers in California.
Other emergency medicine in Sacramento
- Gregory HachigianSacramento$10.9M
- Masaru OshitaSacramento$7.9M
- Eric GrossSacramento$185K
- Jeffrey OvercashChula Vista$31.8M
- Todd SimmonsEscondido$19.9M
- Michael WatersChula Vista$13.3M
- Barry HellerLong Beach$11.5M
- Brian BearieSan Bernardino$6.5M
- Julie KasarjianRiverside$4.9M
- Anna Ryabets-LienhardLos Angeles$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.